Core Insights - SELLAS Life Sciences Group, Inc. has appointed Dr. Linghua Wang to its Scientific Advisory Board, enhancing its expertise in cancer research and translational science [1][2] - The company aims to leverage Dr. Wang's experience in cancer immunogenomics and computational biology to advance its scientific and clinical strategy during a critical growth phase [2][3] Company Overview - SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for various cancer indications [4] - The lead product candidate, GPS, targets the WT1 protein found in multiple tumor types and has potential as both a monotherapy and in combination with other therapies [4] - The company is also developing SLS009 (tambiciclib), a differentiated small molecule CDK9 inhibitor, which has shown a high response rate in AML patients with unfavorable prognostic factors [4]

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will be added to the Russell 3000 and Russell 2000 Indexes, effective after the U.S. market close on June 27, as part of the 2025 Russell indexes annual reconstitution. The Russell 3000 Index tracks the performance of the la ...

Galena Biopharma, Inc. (SLS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system ...

New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009 Programs as Company Approaches Key Inflection Points This YearNEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the appointment of two distinguished oncology leaders to its Scientific Advisor ...

- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced preclinical eff ...

Core Viewpoint - Solaris Resources Inc. has secured a US$200 million financing arrangement with RGLD Gold AG, which includes a gold stream and net smelter return royalty, aimed at enhancing liquidity and supporting the Warintza project development [2][3][5]. Financing Agreements - The financing package consists of a non-dilutive US$200 million, with US$100 million available immediately, to fund derisking activities and repay the senior secured debt facility [5][6]. - The structure of the financing aligns with Solaris' strategy to maximize shareholder value without dilution, reinforcing Warintza's status as a tier 1 copper asset [3][5]. Project Development - The financing will support technical studies, permitting, early infrastructure development, and general working capital, ensuring the company is funded through to a final investment decision (FID) [6][19]. - The company plans to publish a Pre-Feasibility Study (PFS) in Q3 2025, followed by a Bankable Feasibility Study [19][20]. Strategic Relationships - Partnering with Royal Gold provides competitive capital costs and a strategic relationship that enhances project flexibility [4][5]. - The financing structure allows for future project financing while maintaining strategic optionality around the Warintza project [18]. Exploration Potential - The Stream area of interest is limited, allowing Solaris to retain significant exploration upside, with commercial optionality around high-priority targets within the Warintza district [9][15]. - The company is also advancing exploration across its broader land package of over 260 km², which includes several high-priority regional targets [22]. Environmental and Social Commitment - Royal Gold has committed to financially support Solaris' environmental and social programs, reflecting a commitment to sustainable development and stakeholder engagement [17].

Core Insights - SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapies for various cancer indications [2] - The company’s lead product candidate, GPS, targets the WT1 protein and has potential applications as both a monotherapy and in combination with other therapies for hematologic malignancies and solid tumors [2] - SELLAS is also developing SLS009, a differentiated small molecule CDK9 inhibitor, which shows promise in treating AML patients with unfavorable prognostic factors [2] Event Participation - Dr. Angelos Stergiou, President and CEO of SELLAS, will participate in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2025, at 8:20 am ET [1][2] Company Overview - SELLAS Life Sciences Group, Inc. is dedicated to the development of innovative therapeutics for a wide range of cancer types [2] - The company’s lead candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets a protein present in various tumor types [2] - SLS009 is positioned as potentially the first and best-in-class CDK9 inhibitor with reduced toxicity and increased potency compared to existing options [2]

Core Insights - SELLAS Life Sciences Group, Inc. has initiated dosing of the first pediatric acute myeloid leukemia (AML) patient in a Phase 2 trial for SLS009, a selective CDK9 inhibitor, supported by Rare Pediatric Disease Designation [1][2] Group 1: Clinical Development - The Phase 2 trial is an open-label, single-arm, multi-center study aimed at evaluating the safety, tolerability, and efficacy of SLS009 in combination with venetoclax and azacitidine at two dose levels: 45 mg and 60 mg [3] - The target response rate for the optimal dose level is set at 20%, with a target median survival of at least 3 months [3] - The trial includes cohorts for ASXL1-mutated AML patients and those with myelodysplasia-related molecular abnormalities, aiming to identify biomarkers for the target patient population [3] Group 2: Regulatory and Market Implications - SELLAS received FDA Rare Pediatric Disease Designation for SLS009 in July 2024, which may provide regulatory advantages and eligibility for a Priority Review Voucher (PRV) upon future NDA approval [2] - PRVs have recently been valued at approximately $100 million, indicating significant market potential for the company if successful [2] Group 3: Company Overview - SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel therapies for various cancer indications, with its lead product candidate GPS targeting the WT1 protein [4] - SLS009 is positioned as a potentially first-in-class CDK9 inhibitor, demonstrating a high response rate in AML patients with unfavorable prognostic factors, including ASXL1 mutation [4]

Clinical Trial Results - SLS009 demonstrated a median overall survival (mOS) of 8.9 months in AML-MRC patients and 8.8 months in all relapsed or refractory patients, significantly exceeding the historical benchmark of 2.5 months[3] - The ongoing Phase 2 trial of SLS009 achieved an overall response rate (ORR) of 67% in AML-MRC patients and 46% in all evaluable patients, surpassing the targeted 20% ORR[3] - The final analysis of the Phase 3 REGAL trial of GPS in AML is anticipated later in 2025, with preliminary signals of effectiveness noted in the interim analysis[7] - SLS009 showed promising efficacy in pediatric acute lymphoblastic leukemia (ALL) xenograft models, with median survival tripled compared to the control arm[9] - The company plans to present further data on SLS009 at the ASCO 2025 conference, focusing on its efficacy in ASXL1-mutated colorectal cancer[6] Financial Performance - As of March 31, 2025, SELLAS reported cash and cash equivalents of approximately $28.4 million, with an additional $4.0 million received from warrant exercises in April 2025[5][14] - Research and development expenses for Q1 2025 were $3.2 million, a decrease of $1.9 million compared to $5.1 million in Q1 2024, primarily due to reduced clinical trial expenses[11] - General and administrative expenses for Q1 2025 were $2.9 million, down from $4.5 million in Q1 2024, reflecting a decrease in personnel-related expenses and professional fees[13] - The net loss for Q1 2025 was $5.8 million, or a loss per share of $0.07, compared to a net loss of $9.6 million, or $0.21 per share, in Q1 2024[14] Fundraising Activities - SELLAS raised $25 million in gross proceeds from a registered direct offering, which will be used for working capital and potential acquisitions[10]

Core Insights - SELLAS Life Sciences Group, Inc. announced positive overall survival data from the ongoing Phase 2 trial of SLS009 in relapsed/refractory acute myeloid leukemia (AML), demonstrating a median overall survival (mOS) of 8.9 months in AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 months in all relapsed or refractory patients, significantly exceeding historical benchmarks [1][3][6] - The company reported a cash position of approximately $28.4 million as of March 31, 2025, with an additional $4.0 million received from warrant exercises in April 2025 [1][12] Clinical Developments - The Phase 2 trial of SLS009 showed a 67% overall response rate (ORR) in patients with AML-MRC and 46% in all evaluable patients, surpassing the targeted 20% ORR [3] - Preclinical data presented at the 2025 AACR Conference indicated that SLS009 can induce apoptosis in TP53 mutated AML by targeting proteins like MCL-1 and survivin, achieving up to 97% reduction in TP53-mutated leukemia cell populations [4] - Promising preclinical efficacy of SLS009 in ASXL1 mutated colorectal cancer will be showcased at ASCO 2025 [5] Financial Performance - Research and development expenses for Q1 2025 were $3.2 million, down from $5.1 million in Q1 2024, primarily due to reduced clinical trial expenses [10] - General and administrative expenses decreased to $2.9 million in Q1 2025 from $4.5 million in Q1 2024, attributed to lower personnel-related expenses and professional fees [11] - The net loss for Q1 2025 was $5.8 million, or $0.07 per share, compared to a net loss of $9.6 million, or $0.21 per share, in Q1 2024 [12][17] Corporate Updates - The interim analysis of the Phase 3 REGAL trial of Galinpepimut-S (GPS) in AML indicated preliminary signals of effectiveness, with fewer than 50% of enrolled patients confirmed deceased after a median follow-up of 13.5 months [6] - A Phase 2a trial of SLS009 in combination with zanubrutinib in DLBCL showed an ORR of 67%, with one complete response and three partial responses among responders [7] - The company raised $25 million from a registered direct offering to strengthen its financial position for working capital and potential acquisitions [9]